ArticleBiomolecules & biomedicine2026
LODDS-based nomogram for breast cancer-specific survival in surgically treated breast cancer in young patients.
Article in Biomolecules & biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditional tumor staging relies on absolute lymph node counts, making it susceptible to stage migration, particularly in young breast cancer (YBC) patients with aggressive disease. This study assessed the prognostic value of the continuous log odds of positive lymph nodes (LODDS) for breast cancer-specific survival (BCSS) and developed a predictive nomogram utilizing data from 9,989 surgically treated YBC patients (aged 20-39) sourced from the Surveillance, Epidemiology, and End Results (SEER) database (2010-2015). A multivariable Cox proportional hazards model, adjusted to account for non-proportional hazards, established continuous LODDS as an independent risk factor for poorer BCSS (hazard ratio [HR] = 1.60, 95% confidence interval [CI]: 1.45-1.77, p < 0.001), without relying on data-driven dichotomization. We constructed a nomogram that integrates continuous LODDS with clinicopathological features selected via least absolute shrinkage and selection operator (LASSO). Under a 1,000-resample bootstrap optimism-correction, the nomogram exhibited strong discriminatory power (corrected concordance index [C-index] = 0.777), surpassing the traditional tumor-node-metastasis (TNM) staging model (C-index = 0.736). Moreover, the continuous LODDS-integrated model improved 5-year mortality risk reclassification (continuous net reclassification improvement [NRI] = 0.278, integrated discrimination improvement [IDI] = 0.034; both p < 0.001). The model also demonstrated high calibration accuracy (5-year Brier score = 0.0757) and presented a greater estimated net benefit in Decision Curve Analysis (DCA). In conclusion, continuous LODDS offers critical incremental prognostic information beyond traditional staging. The proposed nomogram serves as an internally validated prediction model for risk stratification in YBC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.